2023-01-25 13:30:00

Hebrew University' Yissum and Israeli Biotech Clearmind Medicines Psychedelic-Derived Obesity Treatment Presented by...

Logo GlobeNewswire

Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the largest annual analytical chemistry conferences in the world

Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (Clearmind or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating obesity, presented the latest results at Isranalytica 2023.

The presentation, titled "The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Obesity and its Metabolic Complications," included data from recently announced pre-clinical results demonstrating efficacy of Clearminds drug candidate MEAI for treating obesity and metabolic syndrome.

Isranalytica 2023, the Annual Meeting of the Israel Analytical Chemical Society, ranks as one of the worlds largest annual analytical chemistry conferences. Professor Joseph Tam, D.M.D., Ph.D., heads the Obesity and Metabolism Laboratory, and he is an Associate Professor of Pharmacology at the Hebrew Universitys Institute for Drug Research. Along with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as part of Clearminds robust collaboration with the Hebrew University and its technology transfer companyYissum.

We are honored that our research partner, Professor Joseph Tam, chose to present the promising results of our MEAI-based treatment for obesity to professionals and medical peers," said Clearmind's CEO Dr. Adi Zuloff-Shani. "One of our targets is to expand the awareness to our unique treatments among the scientific and medical community, as a wide network will facilitate our future clinical programs."

AboutClearmindMedicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The companys intellectual portfolio currently consists of seven patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq and the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol CWY.

For further information visit:https://www.clearmindmedicine.comor contact:

Investor Relations


Telephone: (604) 260-1566

General Inquiries




Yissum is the technology transfer company of The Hebrew University of Jerusalem. Founded in 1964, it serves as a bridge between cutting-edge academic research and a global community of entrepreneurs, investors, and industry. Yissums mission is to benefit society by converting extraordinary innovations and transformational technologies into commercial solutions that address our most urgent global challenges. Yissum has registered over 11,000 patents globally; licensed over 1,140 technologies and has spun out more than 200 companies. Yissums business partners span the globe and include companies such as Boston Scientific, ICL, Intel, Johnson & Johnson, Merck, Novartis and many more. For further information please visitwww.yissum.co.il


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the results of preclinical trials, conducting future trials, the results of future projects, the submission of patent applications and that psychedelic based treatments hold potential to address and provide dedicated solutions for various mental health conditions. Forward-looking statements are not historical facts, and are based upon managements current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that managements expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Companys reports filed from time to time with the Securities and Exchange Commission (SEC), including, but not limited to, the risks detailed in the Companys final prospectus (registration No. 333-265900) filed with the SEC on November 16, 2022. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Continue read on globenewswire.com

Logo GlobeNewswire
SciencePress Release2023-01-19 14:00:00
The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearminds IP portfolio Tel...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:03:00
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience...

Logo PR Newswire
HealthPress Release2023-01-24 17:40:00
SILVER SPRING, Md., Jan. 24, 2023 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 21:52:00
Open Source Diabetes Nonprofit Brings Community-Led Innovation in the Form of the First iPhone-Controlled Interoperable Automated Glycemic Controller for...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo PR Newswire
HealthPress Release2023-01-25 13:05:00
- Phase 2a '201' clinical trial will resume immediately at 50 and 100 mg doses- -Additional safety and pharmacokinetic information will be measured in...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
FDA decision expected by PDUFA target action date of March 22, 2023 If approved, rezafungin will be the first new drug for the treatment of candidemia and...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (First Wave BioPharma or the Company), a clinical-stage...

Logo GlobeNewswire
The global genitourinary drugs market size was valued at USD 32 billion in 2021 and is expected to surpass USD 68.51 billion by 2030, registering a CAGR of...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 16:13:00
ClostraBio, a biotech company focused on developing novel therapeutic solutions for diseases of the gut, is excited to announce a major breakthrough in...

Logo GlobeNewswire
SciencePress Release2023-01-17 14:00:00
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction...

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
TNG908 granted Orphan Drug Designation in U.S. for the treatment of malignant glioma BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc....

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-24 19:10:00
- Wednesday, January 25, 202 3 1 0 : 50 am 11:20am EST - Discussion of the Biotech Showcase Conference BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE)...

Logo GlobeNewswire
SciencePress Release2023-01-25 09:00:00
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider...

Logo GlobeNewswire
SciencePress Release2023-01-05 14:00:00
In a seri es of pre-clinical trials, Clearminds drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin...

Logo GlobeNewswire
SciencePress Release2023-01-24 14:00:00
CARLSBAD, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Qualigen or the Company, Nasdaq: QLGN), a diversified life sciences company...

Logo NewsFileCorp
Press Release2023-01-24 14:00:00
Demonstrable sensitivity and clinical usability of Cognetivity's screening and monitoring tool leaves the company well placed to support the dawning era of...

Logo PR Newswire
HealthPress Release2023-01-25 12:45:00
Addressing market demand for rapid evaluation of novel ingredients, NemaLife enhances the capabilities of its in vivo screening platform LUBBOCK, Texas, Jan....

Logo PR Newswire
TechnologyPress Release2023-01-25 13:30:00
MOUNTAIN VIEW, Calif., Jan. 25, 2023 /PRNewswire/ -- Health Gorilla, a Health Information Network (HIN) and leading interoperability platform, has launched...